TSXV:LBL

Stock Analysis Report

Executive Summary

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide.

Snowflake

Fundamentals

Slightly overvalued with imperfect balance sheet.

Share Price & News

How has Lattice Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

25.0%

LBL

2.9%

CA Biotechs

-0.2%

CA Market


1 Year Return

-16.7%

LBL

-16.4%

CA Biotechs

1.1%

CA Market

Return vs Industry: LBL matched the Canadian Biotechs industry which returned -16.4% over the past year.

Return vs Market: LBL underperformed the Canadian Market which returned 1.1% over the past year.


Shareholder returns

LBLIndustryMarket
7 Day25.0%2.9%-0.2%
30 Day0%-14.2%-3.3%
90 Day0%-16.7%-1.6%
1 Year-16.7%-16.7%-16.4%-16.4%4.6%1.1%
3 Year-89.6%-89.6%-16.3%-16.3%13.1%3.1%
5 Yearn/a16.2%16.2%24.7%6.7%

Price Volatility Vs. Market

How volatile is Lattice Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lattice Biologics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: LBL (CA$0.03) is trading below our estimate of fair value (CA$0.28)

Significantly Undervalued: LBL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: LBL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: LBL is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate LBL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LBL has negative assets, so we can't compare its PB Ratio to the CA Biotechs industry average.


Next Steps

Future Growth

How is Lattice Biologics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lattice Biologics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Lattice Biologics performed over the past 5 years?

41.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: LBL is unprofitable, but has reduced losses over the past 5 years at a rate of 41.8% per year.

Accelerating Growth: Unable to compare LBL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LBL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: LBL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: LBL is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: LBL is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Lattice Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: LBL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: LBL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: LBL has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: LBL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: LBL has a high level of physical assets or inventory.

Debt Coverage by Assets: LBL has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable LBL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: LBL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 110.9% per year.


Next Steps

Dividend

What is Lattice Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate LBL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LBL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if LBL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LBL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LBL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Lattice Biologics's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average board tenure


CEO

Guy Cook (54yo)

5.8yrs

Tenure

US$381,500

Compensation

Mr. Guy S. Cook has been the Chief Executive Officer of Lattice Biologics Ltd. since December 23, 2013 and also serves as its President. Mr. Cook served as the Chief Executive Officer and Director of Black ...


CEO Compensation Analysis

Compensation vs. Market: Guy's total compensation ($USD0.00) is too low to compare against companies of similar size in the Canadian market ($USD122.22K).

Compensation vs Earnings: Guy's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

3.8yrs

Average Tenure

Experienced Board: LBL's board of directors are considered experienced (3.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Guy Cook (54yo)

    CEO, President & Director

    • Tenure: 5.8yrs
    • Compensation: US$381.50k

Board Members

  • Donald McInnes (55yo)

    Director

    • Tenure: 25.8yrs
  • Kevin Loud

    Director

    • Tenure: 2.3yrs
  • Guy Cook (54yo)

    CEO, President & Director

    • Tenure: 5.8yrs
    • Compensation: US$381.50k
  • Cathy Thomas

    Independent Director

    • Tenure: 3.8yrs
  • Kerry Zang

    Chair of the Scientific Advisory Board

    • Tenure: 2.3yrs

Company Information

Lattice Biologics Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lattice Biologics Ltd.
  • Ticker: LBL
  • Exchange: TSXV
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$2.336m
  • Shares outstanding: 93.46m
  • Website: https://www.latticebiologics.com

Location

  • Lattice Biologics Ltd.
  • 512 East Madison Avenue
  • Suite 101
  • Belgrade
  • Montana
  • 59714
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LBLTSXV (TSX Venture Exchange)YesVoting Common SharesCACADDec 2015
B5G2DB (Deutsche Boerse AG)YesVoting Common SharesDEEURDec 2015
LBLT.FOTCPK (Pink Sheets LLC)YesVoting Common SharesUSUSDDec 2015

Biography

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 23:32
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.